

Monitoring Parameters For Psychotropic Medications

ANTIPSYCHOTIC MEDICATIONS

ANTIPSYCHOTIC MEDICATIONS			
GENERIC	BRAND	GENERIC	BRAND
Aripiprazole	Abilify/Maintena, Aristada	Molindone	Moban
Asenapine	Saphris, Secuado	Olanzapine	Zyprexa, Zyprexa Zydis, Zyprexa Relprevv
Brexipiprazole	Rexulti	Olanzapine combination	Lybalvi (olanzapine/samidorphan), Symbyax (olanzapine/fluoxetine)
Cariprazine	Vraylar	Paliperidone	Invega, Invega Sustenna/Trinza/Hafyera
Chlorpromazine	Thorazine	Perphenazine	Trilafon
Clozapine	Clozaril, Fazaclor, Versacloz	Pimavanserin	Nuplazid
Droperidol	Inapsine	Pimozide	Orap
Fluphenazine, Fluphenazine D	Prolixin, Prolixin D	Quetiapine	Seroquel, Seroquel XR
Haloperidol, Haloperidol D	Haldol, Haldol D	Risperidone	Risperdal/Consta, Perseris, Risperdal M
lloperidone	Fanapt	Thioridazine	Mellaril
Loxapine	Loxitane	Thiothixene	Navane
Lumateperone	Caplyta	Trifluoperazine	Stelazine
Lurasidone	Latuda	Ziprasidone	Geodon

MONITORING	ANTIPSYCHOTIC FREQUENCY OF MONITORING
AIMS (Abnormal Involuntary Movement Scale)	On initiation of any antipsychotic medication and at least annually thereafter, or more frequently as clinically indicated.
BLOOD PRESSURE, LIPIDS, FASTING GLUCOSE/HbA1c	On initiation of any antipsychotic medication, at 12 weeks, and at least annually thereafter, or more frequently as clinically indicated.
WAIST CIRCUMFERENCE	On initiation of any antipsychotic medication and at least annually thereafter, or more frequently as clinically indicated.
WEIGHT, HEIGHT & BODY MASS INDEX (BMI)	On initiation of any antipsychotic medication followed by monthly for three months and then at least every three months thereafter, or more frequently as clinically indicated.
CBC w/ ANC, PROLACTIN, TSH	As clinically indicated.
PREGNANCY TEST	For women of childbearing potential.
QT PROLONGATION (assess presence of risk factors including personal history of syncope, family history of sudden death < age 40, cardiac risks) https://crediblemeds.org/	As clinically indicated. Request ECG if the initial evaluation suggests the presence of cardiac risk factors, taking two or more QTc-prolonging medications, including antipsychotics that have been established to have an increased risk of TdP and sudden death (chlorpromazine, droperidol, iloperidone, pimozide, thioridazine, or ziprasidone) or taking other drugs with interactions or side effects that increase risk (e.g., loop diuretics).

CLOZAPINE MONITORING

MONITORING	FREQUENCY OF MONITORING
Complete Blood Count (CBC) w/ Absolute Neutrophil Count (ANC)	Weekly for first 6 months (if values within normal limits), every 2 weeks for second 6 months, then every 4 weeks (if values within normal limits)
Comprehensive Metabolic Panel (CMP)	At least annually
Fasting Lipid Panel	At least annually
Pregnancy Test	For women of childbearing potential.

LITHIUM MONITORING

MONITORING	FREQUENCY OF MONITORING
Lithium Level	At least once weekly until levels are stable, every 2 to 3 months for first 6 months, then at least every 6 months thereafter or more frequently as clinically indicated.
Thyroid Function	Once or twice during the first 6 months, and at least annually thereafter or more frequently as clinically indicated.
CBC	On initiation of lithium and at least annually thereafter or more frequently as clinically indicated.
CMP	Renal function – every 2 to 3 months during the first 6 months, and at least annually thereafter or more frequently as clinically indicated.
ECG with rhythm strip	For all patients >40 years of age or with cardiac risk factors, and as clinically indicated.
Pregnancy Test	For women of childbearing potential.

VALPROIC ACID MONITORING

MONITORING	FREQUENCY OF MONITORING
Valproic Acid Level	Obtain 2 levels to establish therapeutic dose, then as clinically indicated.
CMP & CBC with Platelet Count	On initiation of valproic acid or divalproex and every 3 months for the first year, and at least annually thereafter or more frequently as clinically indicated.
Pregnancy Test	For women of childbearing potential.

CARBAMAZEPINE/OXCARBAZEPINE MONITORING

MONITORING	FREQUENCY OF MONITORING
Carbamazepine Level	Obtain 2 levels to establish therapeutic dose, separated by 4 weeks, then as clinically indicated.
CMP & CBC w/ Platelet Count	On initiation of carbamazepine/oxcarbazepine and monthly for the first 3 months, and at least annually thereafter or more frequently as clinically indicated.

LAMOTRIGINE MONITORING	
MONITORING	FREQUENCY OF MONITORING
Skin rash	As clinically indicated.

Updated April 2023.

References:

- 1) Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. *Am J Psychiatry*. 2020 Sep 1;177(9):868-872.
- 2) American Diabetes Association,, American Psychiatric Association,, American Association of Clinical Endocrinologists,, North American Association for the Study of Obesity; Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. *Diabetes Care* 1 February 2004; 27 (2): 596–601. <https://doi.org/10.2337/diacare.27.2.596>.
- 3) American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). *Am J Psychiatry*. 2002;159(suppl 4):1-50
- 4) Ng F, Mammen OK, Wilting I, et al; International Society for Bipolar Disorders. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. *Bipolar Disord*. 2009;11(6):559-595.
- 5) Walkup J; Work Group on Quality Issues. Practice parameter on the use of psychotropic medication in children and adolescents. *J Am Acad Child Adolesc Psychiatry*. 2009 Sep;48(9):961-973. doi: 10.1097/CHI.0b013e3181ae0a08.
- 6) Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2022. Available at: <http://www.clinicalpharmacology-ip.com/> (accessed Apr. 2023).
- 7) Micromedex® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com/> (accessed Apr. 2023).